DEF: Dyadic International Sets Date for 2025 Annual Shareholder Meeting, Outlines Key Proposals

Dyadic International announces its 2025 Annual Meeting of Shareholders to be held virtually on June 20, 2025, featuring proposals including director election, auditor ratification, and executive compensation advisory votes.

Summary

• Dyadic International will hold its 2025 Annual Meeting of Shareholders virtually on June 20, 2025.
• Shareholders will vote on the election of one Class III director, ratification of Crowe LLP as the independent auditor, an advisory vote on executive compensation, and an advisory vote on the frequency of executive compensation votes.
• The record date for determining shareholders eligible to vote is April 24, 2025.
• The board recommends voting FOR the election of the director, ratification of the auditor, approval of executive compensation, and a yearly frequency for executive compensation votes.
• As of April 24, 2025, directors and executive officers owned approximately 29.5% of the outstanding common stock.
• The company's executive compensation program aims to attract, retain, and reward personnel, aligning their interests with those of shareholders.
• The company's net loss was approximately $9.7 million in 2022, $6.8 million in 2023, and $5.8 million in 2024.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the upcoming shareholder meeting and related proposals. While it highlights some positive aspects of the company's governance and compensation practices, it also acknowledges the company's history of net losses. The overall sentiment is moderately positive due to the forward-looking nature of the meeting and the board's recommendations.

Positives

• The company is providing internet distribution of proxy materials to expedite receipt by shareholders, reduce costs, and conserve paper.
• The board is actively involved in overseeing the management of the company's risks.
• The company has a Code of Conduct and Ethics applicable to all employees, officers, and directors.
• The company's executive compensation program is designed to attract and retain high-caliber executives.
• The company was in compliance with its covenants with respect to the Convertible Notes as of April 24, 2025.

Negatives

• The company has a history of net losses, with a net loss of approximately $5.8 million in 2024.
• Two directors, Michael Tarnok and Arindam Bose, will be retiring effective at the Annual Meeting, reducing the board size to four members.
• The company relies on third parties, which could pose risks to its operations.
• The company faces intellectual property risks.

Risks

• Market and regulatory acceptance of the company's microbial protein production platforms and other technologies is uncertain.
• The company faces competition from alternative technologies.
• The company's capital needs could impact its ability to execute its strategy.
• Changes in global economic and financial conditions could adversely affect the company.
• The company's reliance on information technology exposes it to potential risks.
• Government regulations and environmental, social, and governance issues could impact the company.
• The company faces intellectual property risks.

Future Outlook

The company provides forward-looking statements regarding its expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, but cautions that these statements involve risks and uncertainties.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but it does mention the company's strategic research and development, manufacturing, and marketing relationships with U.S. and international partners.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• Without specific details, it's difficult to assess Dyadic's performance against industry peers like Novozymes, Genencor (Danisco), or DSM in terms of enzyme development and commercialization.
• Similarly, in biopharmaceuticals, comparisons to companies like Sanofi (mentioned as a potential partner) would require more detailed information on collaboration terms and development progress.

Management Changes

Corporate Governance

Related Party Transactions

• On March 8, 2024, the Company issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 in a private placement.
• As of April 24, 2025, $127,496 of interest had been paid, and Convertible Notes payable consisted of the following: Holder Convertible Note Principal Conversion to Common Stock Principal Outstanding Francisco Trust dated 2/28/1996 (1) $1,000,000 $1,000,000 Bradley Emalfarb (2) $500,000 $(500,000) Bradley Scott Emalfarb Irrevocable Trust (2) $410,000 $(410,000) Emalfarb Descendent Trust (3) $90,000 $90,000 Other (non-related persons) $4,000,000 $4,000,000 Total $6,000,000 $(910,000) $5,090,000

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and direction.
• Employees are affected by the company's compensation policies and human capital management practices.
• The company's performance and strategic decisions impact its customers, suppliers, and creditors.

Next Steps

• Shareholders are encouraged to vote on the proposals before the Annual Meeting.
• The Board and Compensation Committee will review the voting results and take them into consideration when making future decisions.
• The company will continue to monitor and manage risks related to its business and operations.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Shareholders, Board of Directors, Executive Compensation, Director Election, Auditor Ratification, Corporate Governance, Dyadic International